Adult children can now compare at-home weekly Leqembi Iqlik shots starting on day one against biweekly infusion-center IV treatment for early Alzheimer's. Leqembi Iqlik (lecanemab-irmb) is an antibody drug that targets amyloid-beta in the brain. The FDA approved the once-weekly subcutaneous injection as an initiation dose for early Alzheimer's disease on July 13, 2026, according to Eisai and Biogen in the FDA approval notice.
The starting regimen is 500 mg once weekly as two back-to-back 250 mg autoinjector shots. Eisai and Biogen made the initiation autoinjector available in the U.S. in late August 2026 through specialty pharmacies, according to Eisai in the company availability update.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does day-one subcutaneous mean?
- Is your parent eligible to start?
- How do the treatment routes compare?
- What safety monitoring still applies?
What does day-one subcutaneous mean?
Day-one means treatment can begin with shots under the skin. No IV induction period is required first. Each weekly dose uses two 250 mg autoinjectors given one after the other. Each injection takes about 15 seconds.
A care partner can learn the at-home routine during training. Families avoid regular infusion-center appointments for the starting phase. This is different from the earlier subcutaneous option. That option allowed only 360 mg weekly maintenance after 18 months of biweekly IV treatment. The 2026 approval covers initiation.
Is your parent eligible to start?
Treatment is for adults with mild cognitive impairment or mild dementia due to Alzheimer's. A doctor must confirm amyloid-beta pathology with testing. Adult children can help gather records and arrange evaluation.
Eligibility is narrow by design. Early-stage disease plus confirmed amyloid matters most. A dementia specialist makes the final decision.
- Ask whether memory symptoms fit mild cognitive impairment or mild dementia
- Confirm amyloid-beta testing is completed or scheduled
- List current blood thinners, bleeding risks, and brain-scan history
- Clarify who will give weekly shots and attend follow-up scans
How do the treatment routes compare?
Families now choose between two ways to begin, then two ways to continue. The new route starts at home with weekly 500 mg subcutaneous injections. The established route starts with 10 mg/kg IV every two weeks at an infusion center. Extension data from the Clarity AD trial showed comparable results.
Once-weekly 500 mg subcutaneous dosing showed 104% drug exposure versus IV every two weeks, with comparable amyloid clearance and safety. That comparison helps families weigh convenience against supervision. Consider travel distance, work schedules, needle comfort, and clinic support. Some families prefer clinic oversight. Others prefer fewer appointments and home dosing.
- At-home weekly initiation: two quick shots, no infusion chair, caregiver handles dosing
- Biweekly IV induction: clinic staff give infusions, travel and chair time required
- After induction: monthly IV or 360 mg weekly subcutaneous maintenance
What safety monitoring still applies?
Leqembi carries a boxed warning for ARIA. ARIA means brain swelling and bleeding linked to amyloid-targeting treatment. The FDA label states the warning, according to the FDA in the current DailyMed label. People with two copies of the ApoE epsilon-4 gene face higher risk.
Doctors order a baseline brain MRI plus periodic MRIs during treatment. Report severe headache, confusion, vision changes, dizziness, or falls right away. Ask the prescriber when scans occur and where results go. Keep a simple calendar for shots, symptoms, and MRIs. Bring that record to every visit.
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Memory Clinic Patients Can Avoid Overreading the Headline
